Wilma Bilger
Overview
Explore the profile of Wilma Bilger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buhler K, Fischer R, Verpillat P, Allignol A, Guedes S, Boutmy E, et al.
Reprod Biol Endocrinol
. 2021 Jun;
19(1):90.
PMID: 34134695
Background: This study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f) with urinary highly purified human menopausal gonadotropin (hMG HP; Menogon HP), during assisted reproductive technology (ART)...
2.
Fatemi H, Bilger W, Denis D, Griesinger G, La Marca A, Longobardi S, et al.
Reprod Biol Endocrinol
. 2021 May;
19(1):68.
PMID: 33975610
Background: Individualization of the follicle-stimulating hormone (FSH) starting dose is considered standard clinical practice during controlled ovarian stimulation (COS) in patients undergoing assisted reproductive technology (ART) treatment. Furthermore, the gonadotropin...
3.
Lunenfeld B, Bilger W, Longobardi S, Kirsten J, DHooghe T, Sunkara S
Gynecol Endocrinol
. 2019 Aug;
35(12):1027-1036.
PMID: 31392906
It is essential that fertility treatment is individualized based on a thorough diagnostic work-up, with treatment tailored to the patients' requirements. This individualization should be kept in mind during the...
4.
Lunenfeld B, Bilger W, Longobardi S, Alam V, DHooghe T, Sunkara S
Front Endocrinol (Lausanne)
. 2019 Jul;
10:429.
PMID: 31333582
The first commercially available gonadotropin product was a human chorionic gonadotropin (hCG) extract, followed by animal pituitary gonadotropin extracts. These extracts were effective, leading to the introduction of the two-step...
5.
Naether O, Tandler-Schneider A, Bilger W
Drug Healthc Patient Saf
. 2015 May;
7:69-76.
PMID: 25926756
Purpose: This postmarketing surveillance survey was conducted to investigate the utility of the CONsistency in r-FSH Starting dOses for individualized tReatmenT (CONSORT) calculator for individualizing recombinant human follicle-stimulating hormone (r-hFSH)...
6.
Nawroth F, Tandler-Schneider A, Bilger W
Drug Healthc Patient Saf
. 2015 May;
7:63-8.
PMID: 25926755
This prospective, noninterventional, post-marketing surveillance study evaluated doses of recombinant human follicle-stimulating hormone (r-hFSH) using the redesigned follitropin alfa pen in women who were anovulatory or oligomenorrheic and undergoing ovulation...
7.
Buhler K, Naether O, Bilger W
Reprod Biol Endocrinol
. 2014 Jan;
12:6.
PMID: 24423045
Background: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) both have a role to play in follicular development during the natural menstrual cycle. LH supplementation during controlled ovarian stimulation (COS) for...
8.
Welcker J, Nawroth F, Bilger W
Reprod Biol Endocrinol
. 2010 Sep;
8:111.
PMID: 20843323
Background: Self-administration of recombinant human follicle-stimulating hormone (r-hFSH) can be performed using injection pen devices by women undergoing assisted reproductive technology procedures. The objective of this study was to explore...